The Immuno-Oncology Assay Market is estimated to be valued at USD 5.6 billion in 2024. The immuno-oncology assay market is predicted to rise at a CAGR of 12.4% from 2024 to 2034. The global immuno-oncology assay market is anticipated to reach USD 18.1 billion by 2034.
The immuno-oncology assay market is experiencing rapid growth, driven by the increasing prevalence of cancer globally and advancements in cancer immunotherapy. Immuno-oncology assays are critical tools for diagnosing cancer, predicting patient responses to treatment, and monitoring therapeutic efficacy by assessing the immune system's interactions with cancer cells.
Technological advancements play a significant role in the market's growth, with next-generation sequencing (NGS), flow cytometry, PCR, and immunoassays continuously improving assay sensitivity, specificity, and multiplexing capabilities. These innovations enable the identification of novel biomarkers and the development of companion diagnostics for personalized cancer treatment strategies.
| Attributes | Key Insights |
|---|---|
| Estimated Market Size in 2024 | USD 5.6 billion |
| Projected Market Value in 2034 | USD 18.1 billion |
| Value-based CAGR from 2024 to 2034 | 12.4% |
Don't pay for what you don't need
Customize your report by selecting specific countries or regions and save 30%!
From 2019 to 2023, the immuno-oncology assay market experienced a CAGR of 15.4%. The approval of immune checkpoint inhibitors revolutionized cancer treatment, leading to a surge in immuno-oncology research and development.
The immuno-oncology assay market witnessed rapid growth, fueled by increasing investments in research and clinical trials. Technological advancements, such as next-generation sequencing and multiplexed immunoassays, improved assay sensitivity and specificity.
Regulatory approvals for companion diagnostics further accelerated market expansion.
The immuno-oncology assay market is expected to evolve further, with a focus on predictive and prognostic biomarkers, early cancer detection, and monitoring of treatment responses. Strategic collaborations, regulatory support, and reimbursement policies will continue to shape market dynamics.
The immuno-oncology assay market is poised for significant growth in the coming years, driven by ongoing advancements in cancer research, therapeutic innovation, and the increasing adoption of personalized medicine approaches in oncology.
Projections indicate that the global immuno-oncology assay market is expected to experience a CAGR of 12.4% from 2024 to 2034.
| Historical CAGR from 2019 to 2023 | 15.4% |
|---|---|
| Forecast CAGR from 2024 to 2034 | 12.4% |
Principal Consultant
South Korea and Japan stand out as the top two revenue-generating countries, as indicated in the table provided. The government and private sector investments in cancer research and immunotherapy initiatives are significant drivers of market growth in South Korea.
Japanese pharmaceutical companies are at the forefront of developing immunotherapy drugs and companion diagnostics. Regulatory support and streamlined approval processes for diagnostic products contribute to market growth.
| Countries | Forecast CAGRs from 2024 to 2034 |
|---|---|
| The United States | 12.1% |
| The United Kingdom | 13.9% |
| China | 13.3% |
| Japan | 14.1% |
| South Korea | 15.2% |
The immune-oncology assay market in the United States is expected to expand at a CAGR of 12.1% by 2034. The United States is at the forefront of cancer immunotherapy research and development, with significant investments from both public and private sectors.
The approval and adoption of novel immunotherapies, such as immune checkpoint inhibitors and CAR-T cell therapies, have propelled the demand for immuno-oncology assays to assess treatment efficacy and patient response.
The United States-based companies and research institutions are driving innovations in immuno-oncology assay technologies, including next-generation sequencing, flow cytometry, and multiplexed immunoassays. These technological advancements enhance assay sensitivity, specificity, and throughput, enabling comprehensive profiling of the tumor microenvironment and immune response.
The immune-oncology assay market in the United Kingdom is expected to expand at a CAGR of 13.9% by 2034. The United Kingdom is home to leading research institutions, universities, and biotechnology companies actively engaged in immuno-oncology research and development.
Collaborative efforts between academia, industry, and government agencies fuel innovation in assay technologies, biomarker discovery, and therapeutic development, driving market growth.
The United Kingdom is a significant hub for clinical trials evaluating immunotherapies across various cancer types. The adoption of immune checkpoint inhibitors, CAR-T cell therapies, and other immunotherapeutic agents in clinical practice is increasing, necessitating the use of immuno-oncology assays for patient selection, treatment monitoring, and outcome prediction.
China faces a significant burden of cancer, with increasing incidence rates due to factors such as aging population, lifestyle changes, and environmental pollution.
This high disease burden drives the demand for immuno-oncology assays for early detection, diagnosis, and treatment monitoring. United Kingdom. The immune-oncology assay market in China is expected to rise at a CAGR of 13.3% by 2034.
The Chinese government has prioritized cancer prevention, diagnosis, and treatment as part of its healthcare reforms. Initiatives to improve cancer care infrastructure, enhance access to innovative therapies, and promote research and development in oncology contribute to market growth.
Japan has a growing cancer burden due to factors such as the aging population, lifestyle changes, and environmental factors. The rising prevalence of cancer drives the demand for immuno-oncology assays for early detection, diagnosis, and treatment monitoring. The immune-oncology assay market in Japan is expected to expand at a CAGR of 14.1% by 2034.
Japan has a strong research and development infrastructure in oncology, with leading academic institutions, biotechnology companies, and healthcare centers engaged in cancer research.
The country's contributions to cancer immunotherapy research, including novel therapies and biomarker discovery, fuel the demand for immuno-oncology assays.
South Korea is actively involved in cancer immunotherapy research and development. The adoption of immune checkpoint inhibitors, CAR-T cell therapies, and other immunotherapeutic agents is increasing, driving the demand for immuno-oncology assays to assess treatment efficacy and patient response. The immune-oncology assay market in South Korea is expected to flourish at a CAGR of 15.2% by 2034.
South Korean companies are at the forefront of technological innovation in diagnostics and biotechnology. They are developing advanced immuno-oncology assay platforms, including next-generation sequencing, flow cytometry, and multiplexed immunoassays, to meet the evolving needs of cancer diagnosis and treatment.
Get the data you need at a Fraction of the cost
Personalize your report by choosing insights you need
and save 40%!
The below section shows the leading segment. The reagents and antibodies segment is to rise at a CAGR of 12.2% from 2024 to 2034. Based on technology, the checkpoint inhibitors segment is anticipated to hold a dominant share through 2034. It is set to exhibit a CAGR of 11.9% from 2024 to 2034.
| Category | CAGR from 2024 to 2034 |
|---|---|
| Reagents and Antibodies | 12.2% |
| Checkpoint Inhibitors | 11.9% |
Based on type, the Reagents and Antibodies segment is anticipated to proliferate at a CAGR of 12.2% from 2024 to 2034.
Reagents and antibodies are essential components of immuno-oncology assays, playing crucial roles in detecting specific biomarkers, antigens, or immune cell markers associated with cancer and immunotherapy response.
Reagents and antibodies are highly specific and sensitive, allowing for the accurate detection and quantification of targets of interest in complex biological samples, such as blood, tissue, or tumor specimens.
Many immuno-oncology assays require multiplexing, where multiple targets are detected simultaneously in a single assay. Reagents and antibodies with multiplexing capabilities enable comprehensive profiling of the immune response and tumor microenvironment, providing valuable insights for cancer diagnosis and treatment.
Based on technology, the checkpoint inhibitors segment is anticipated to rise at a CAGR of 11.9% from 2024 to 2034.
Checkpoint inhibitors have revolutionized cancer treatment by enhancing the body's immune response against cancer cells. These therapies block inhibitory checkpoints, such as PD-1/PD-L1 and CTLA-4, allowing the immune system to recognize and attack cancer cells more effectively.
Biomarkers such as PD-L1 expression levels have been identified as predictors of response to checkpoint inhibitor therapy. Immuno-oncology assays are used to measure these biomarkers, allowing clinicians to identify patients who are most likely to respond to checkpoint inhibitors and tailor treatment accordingly.
The growing number of clinical trials investigating checkpoint inhibitors and combination therapies underscores their importance in immuno-oncology research. Immuno-oncology assays play a crucial role in these trials by assessing biomarker expression, immune cell profiling, and treatment responses.
Collaboration with academic institutions, research organizations, and biotechnology companies enables market players to access complementary expertise, technologies, and resources.
Partnerships facilitate biomarker discovery and validation, clinical validation studies, and the development of companion diagnostics. Collaborations also enhance market penetration, accelerate product development, and mitigate development risks.
| Attributes | Details |
|---|---|
| Estimated Market Size in 2024 | USD 5.6 billion |
| Projected Market Valuation in 2034 | USD 18.1 billion |
| Value-based CAGR 2024 to 2034 | 12.4 % |
| Forecast Period | 2024 to 2034 |
| Historical Data Available for | 2019 to 2023 |
| Market Analysis | Value in USD billion |
| Key Regions Covered | North America; Latin America; Western Europe; Eastern Europe; South Asia and Pacific; East Asia; Middle East and Africa |
| Key Market Segments Covered | Product, Technology, Indication, End-user, Application, Region |
| Key Countries Profiled | The United States, Canada, Brazil, Mexico, Germany, The United Kingdom, France, Spain, Italy, Russia, Poland, Czech Republic, Romania, India, Bangladesh, Australia, New Zealand, China, Japan, South Korea, GCC countries, South Africa, Israel |
| Key Companies Profiled | AGILENT TECHNOLOGIES; Sartorius AG; NanoString Technologies; THERMO FISHER SCIENTIFIC; BIO-RAD LABORATORIES; F. HOFFMANN-LA ROCHE LTD.; PERKINELMER; ILLUMINA; QIAGEN N.V.; Charles River Laboratories |
As of 2024, the market for immune oncology assays is expected to be valued at USD 5.6 billion.
By 2034, the market value of immuno-oncology assays is expected to reach USD 18.1 billion.
From 2024 to 2034, the immuno-oncology assay market is expected to flourish at a CAGR of 12.4%
The reagent and antibodies segment is expected to rise at a CAGR of 12.2% from 2024 to 2034.
South Kore is likely the top-performing market, with a CAGR of 15.2%.
1. Executive Summary
2. Market Overview
3. Market Background
4. Global Market Analysis 2019 to 2023 and Forecast, 2024 to 2034
5. Global Market Analysis 2019 to 2023 and Forecast 2024 to 2034, By Product
5.1. Reagents and Antibodies
5.2. Instruments
5.3. Software
5.4. Consumables and Accessories
6. Global Market Analysis 2019 to 2023 and Forecast 2024 to 2034, By Technology
6.1. Checkpoint Inhibitors
6.2. Cytokines & Immunomodulators
6.3. Monoclonal Antibodies
6.4. Other Technologies
7. Global Market Analysis 2019 to 2023 and Forecast 2024 to 2034, By Indication
7.1. Melanoma
7.2. Colorectal Cancer
7.3. Lung Cancer
7.4. Other Cancers
8. Global Market Analysis 2019 to 2023 and Forecast 2024 to 2034, By End-Users
8.1. Hospitals
8.2. Clinics
8.3. Cancer Research Centers
9. Global Market Analysis 2019 to 2023 and Forecast 2024 to 2034, By Application
9.1. Research Applications
9.2. Clinical Diagnostics
10. Global Market Analysis 2019 to 2023 and Forecast 2024 to 2034, By Region
10.1. North America
10.2. Latin America
10.3. Western Europe
10.4. Eastern Europe
10.5. South Asia and Pacific
10.6. East Asia
10.7. Middle East and Africa
11. North America Market Analysis 2019 to 2023 and Forecast 2024 to 2034, By Country
12. Latin America Market Analysis 2019 to 2023 and Forecast 2024 to 2034, By Country
13. Western Europe Market Analysis 2019 to 2023 and Forecast 2024 to 2034, By Country
14. Eastern Europe Market Analysis 2019 to 2023 and Forecast 2024 to 2034, By Country
15. South Asia and Pacific Market Analysis 2019 to 2023 and Forecast 2024 to 2034, By Country
16. East Asia Market Analysis 2019 to 2023 and Forecast 2024 to 2034, By Country
17. Middle East and Africa Market Analysis 2019 to 2023 and Forecast 2024 to 2034, By Country
18. Key Countries Market Analysis
19. Market Structure Analysis
20. Competition Analysis
20.1. AGILENT TECHNOLOGIES
20.2. Sartorius AG
20.3. NanoString Technologies
20.4. THERMO FISHER SCIENTIFIC
20.5. BIO-RAD LABORATORIES
20.6. F. HOFFMANN-LA ROCHE LTD.
20.7. PERKINELMER
20.8. ILLUMINA
20.9. QIAGEN N.V.
20.10. Charles River Laboratories
21. Assumptions & Acronyms Used
22. Research Methodology
Explore Healthcare Insights
View Reports
Immuno Oncology Assay Market
